The body's endocannabinoid system (ECS) plays a significant role in regulating sleep, mood, pain, and stress — the very systems that, when dysregulated, often underlie sleep disorders. ECS receptors (CB1 and CB2) are distributed throughout the brain regions governing sleep-wake cycles, including the hypothalamus and brainstem.
Emerging research suggests that disturbances in ECS function may contribute to chronic insomnia — particularly where anxiety, chronic pain, or PTSD are co-occurring. This has generated growing clinical interest in cannabis-based medicinal products (CBMPs) as a potential treatment consideration in sleep medicine.
Cannabis-based medicines have been legally prescribable in the UK since November 2018, when the government rescheduled them from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. They are Prescription Only Medicines (POMs) available exclusively through specialist clinicians following thorough individual assessment.
Important:
Cannabis-based medicines are not a first-line or universal treatment for sleep disorders. They may be considered by specialist clinicians only where appropriate first-line treatments have been tried and found insufficient. All prescribing decisions are made on an individual, clinical basis. This content is for education only and does not constitute medical advice.